Neogen Corporation
HealthcareNASDAQ:NEOG · NASDAQ Global Select
-$0.15 today
Vol 1.23M · Avg 2.60M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-52.7%
avg 1.4%
ROIC
0.3%
avg 6.1%
ROA
-31.7%
avg 2.8%
Analysis
ROIC is currently the strongest return metric at 0.3% versus its period average of 6.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Mikhael Nassif | Chief Executive Officer, President & Director | $1.22M | — | — | $704.00 | <0.01% |
Jeremy Yarwood | Chief Scientific Officer | $476,992.00 | — | — | — | — |
Kevin Burke | Chief Human Resources Officer | — | — | 57 | — | — |
R. Bryan Riggsbee | Chief Financial Officer & Senior Vice President | — | — | 56 | $459,713.00 | 0.21% |
Jennifer Evans Stacey | Chief Legal & Compliance Officer and Board Secretary | — | — | 61 | $39,349.00 | 0.02% |
Tamara A. Ranalli | Senior VP & GM of Global Food Safety | — | — | 52 | $50,813.00 | 0.02% |
Bill Waelke | Head of Investor Relations | — | — | — | — | — |
Joe Freels | Senior VP & Chief Commercial Officer | — | — | — | — | — |
John Moylan | Vice President, Corporate Controller & Chief Accounting Officer | — | — | — | $23,571.00 | 0.01% |
Sarah Demey | Administrative Manager | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$3,123.12
Sells
0
$0.00
Net Sentiment
+$3,123.12
Net buying
Most Active
Nassif Mikheal
5 transactions
Analysis
Insiders reported 5 buys worth $3,123.12 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $3,123.12. Nassif Mikheal was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +12.3% | +2.6% (15yr)1 analysts |
| Revenue | N/A | N/A | +15.4% | +7.5% (15yr)1 analysts |
| Net Income | N/A | N/A | +14.2% | +8.1% (15yr)1 analysts |
| EBIT | N/A | N/A | +16.3% | N/A1 analysts |
Analysis
Recent growth has been strongest in EBIT at +16.3% over three years. Forward estimates point to Net Income at +8.1% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
NovoCure Limited
NASDAQ:NVCR
$2.06B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.36B
BioLife Solutions, Inc.
NASDAQ:BLFS
$1.28B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.22B
OPKO Health, Inc.
NASDAQ:OPK
$1.07B
CONMED Corporation
NYSE:CNMD
$1.05B
Azenta, Inc.
NASDAQ:AZTA
$1.04B
Zenas BioPharma, Inc.
NASDAQ:ZBIO
$883.93M
Tilray Brands, Inc.
NASDAQ:TLRY
$595.63M
Upstream Bio, Inc.
UPB
$331.96M
Who manages NEOG?
Neogen Corporation (NEOG) lists 10 active executives. The top listed executive is Jeremy Yarwood, Chief Scientific Officer.
Are NEOG insiders buying or selling?
Recent insider activity shows net buying of $36.18M.
Explore More
Continue the stock analysis
Jump to another research area for this company.